Ranbaxy Laboratories Lipitor

Bloomberg News (1/26, Gale, Schoenberg) reports, 

Ranbaxy Laboratories / Maher Law Firm

        BBC News (1/26) adds. “The legal proceedings do not affect the US sale of Ranbaxy’s generic version of the best-selling drug in the world, cholesterol” medications “Lipitor [atorvastatin].” Moreover, “the filing by the Justice Department on behalf of the FDA must be approved by a federal judge.”

        MedPage Today (1/26, Gever) reports, “The Justice Department filed a consent decree today preventing generic drug giant Ranbaxy from selling drugs made at four of its manufacturing plants until it brings them into compliance with the FDA’s quality standards.” 

        The Star-Ledger – NJ.com (1/26, Todd) quotes Dara Corrigan, FDA associate commissioner for regulatory affairs, who said, “Because this company continued to violate current good manufacturing practice regulations and falsify information on drug applications, the FDA took these actions in an effort to protect consumers.”

Also covering the story is Dow Jones Newswires (1/26, FitzGerald, Subscription Publication)